About 10% of Americans have Type 2 diabetes (T2), often along with obesity and heart disease. As treatment strategies evolve, GLP-1 receptor agonists have emerged as a widely adopted therapeutic option.
Our latest analysis reveals how the characteristics and expectations of people with T2 embarking on GLP-1 therapy have evolved over the last three years, highlighting key trends shaping today’s treatment landscape.
Download the poster for a closer look at the methodology, results, and conclusions of this study.
dQ&A data show that users' perceptions of an algorithm's aggressiveness strongly impact satisfaction and NPS.
Read More
This research excerpt is just the tip of the iceberg. dQ&A has decades of experience across the United States, Canada, and Europe. If you drive critical diabetes research decisions in your organization, dQ&A is the diabetes insight partner that can get the answers you need.
